Side Effects of Sustained-Release Vaginal Suppository Progesterone in Pregnant Women: Gestational Diabetes Mellitus

AUTHORS

Neda Kheyri 1 , Maryam Anbarlooi 1 , soraya saleh gargari 2 , * , Fatemeh Sadat Sarfjoo 3

1 Researcher, Department of obstetrics and gynecology, Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Andorra

2 Department of obstetrics and gynecology, Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Andorra

3 - Researcher, Department of obstetrics and gynecology, Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Andorra

How to Cite: Kheyri N , Anbarlooi M, saleh gargari S, Sarfjoo F S. Side Effects of Sustained-Release Vaginal Suppository Progesterone in Pregnant Women: Gestational Diabetes Mellitus , Ann Mil Health Sci Res. 2013 ; 11(4):e64614.

ARTICLE INFORMATION

Annals of Military and Health Sciences Research: 11 (4); e64614
Published Online: December 02, 2013
Article Type: Original Article
Received: August 24, 2013
Accepted: November 17, 2013

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Evaluation of the potential impact of vaginal progesterone on both mother and fetus is necessary before expanding the indication of this drug especially throughout pregnancy. To evaluate the potential impact of vaginal progesterone on both mother and fetus. Materials and Methods: This case-control study was designed to collect data on the potential gestational diabetes mellitus complication associated with progesterone use comparing maternal and neonatal outcomes between 245pregnant women receiving vaginal suppository of Cyclogest (200mg) and 808controls without progesterone. Results: The incidence of gestational diabetes was 9.8% and 5.2% in case and control groups, respectively (p=0.039). According to linear regression analysis, there was a direct association between duration of progesterone usage and impairment of glucose tolerance test in group of cases (r=0.43; p=0.002). Conclusions: The use of progesterone for the prevention of recurrent preterm delivery could associate with an increased risk of developing gestational diabetes.

Keywords

Drug Administration Vaginal Progesterone Premature Birth Diabetes Gestational

© 2013, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

full text is available in pdf.

References

  • 1.

    References are available in pdf.

  • COMMENTS

    LEAVE A COMMENT HERE: